Relay Therapeutics, Inc. (RLAY) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Relay Therapeutics reported revenue of $15.4M, up 53.4% from $10.0M the year before. Net income was -$276.5M (a -1800.6% net margin), or -$1.61 per diluted share. Operating margin was -1971.6%. Operating activities generated -$235.5M of cash, leaving -$235.9M of free cash flow. At fiscal year end, Relay Therapeutics held $621.3M in total assets against $54.3M in total liabilities, including $84.0M of cash and equivalents.
Open the full interactive Relay Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Relay Therapeutics Key Stats
| Share Price | $17.36 |
|---|---|
| Market Cap | $3.52B |
| Revenue YoY Growth | +53.4% |
| 52-Week Range | $6.03 – $20.75 |
| Shares Outstanding | 202.8 million (basic, 2026 Q2) |
Relay Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $82.7M | $30.3M | $1.4M | $25.5M | $10.0M | $15.4M |
| Operating Income | -$55.8M | -$364.7M | -$299.3M | -$373.0M | -$372.5M | -$302.7M |
| Pre-Tax Income | -$52.4M | -$363.9M | -$290.5M | -$342.0M | -$337.7M | -$276.5M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$52.4M | -$363.9M | -$290.5M | -$342.0M | -$337.7M | -$276.5M |
| Diluted EPS | -$5.40 | -$3.82 | -$2.59 | -$2.79 | -$2.36 | -$1.61 |
Relay Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $7.0M | $3.0M | $350,000 |
| Net Income | -$74.1M | -$54.9M | -$73.3M | -$83.7M |
| Diluted EPS | -$0.43 | — | -$0.41 | -$0.41 |
Relay Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $447.6M | $280.1M | $151.8M | $143.7M | $124.3M | $84.0M |
| Current Assets | $770.1M | $976.2M | $1.02B | $770.1M | $809.2M | $578.3M |
| Total Assets | $799.8M | $1.01B | $1.10B | $844.0M | $871.3M | $621.3M |
| Current Liabilities | $13.6M | $24.3M | $63.7M | $30.3M | $50.7M | $25.6M |
| Total Liabilities | $36.5M | $110.6M | $149.6M | $92.0M | $93.5M | $54.3M |
| Shareholders' Equity | $763.3M | $897.8M | $950.2M | $752.0M | $777.8M | $567.1M |
Relay Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$102.5M | -$74.4M | -$229.5M | -$300.3M | -$249.1M | -$235.5M |
| Cash From Investing | $81.7M | -$479.5M | -$188.7M | $257.6M | -$41.1M | $192.8M |
| Cash From Financing | $426.5M | $388.1M | $289.9M | $34.8M | $270.2M | $1.6M |
| Free Cash Flow | -$104.4M | -$77.9M | -$238.6M | -$304.4M | -$251.1M | -$235.9M |
Figures from Relay Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Relay Therapeutics financials page for every line item.
Relay Therapeutics Company Profile
| Ticker | RLAY |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001812364 |
Frequently Asked Questions
What was Relay Therapeutics' revenue in fiscal 2025?
Relay Therapeutics (RLAY) reported revenue of $15.4M for fiscal 2025.
What is Relay Therapeutics' annual revenue history?
Relay Therapeutics' annual revenue by fiscal year: 2020: $82.7M; 2021: $30.3M; 2022: $1.4M; 2023: $25.5M; 2024: $10.0M; 2025: $15.4M.
What was Relay Therapeutics' net income in fiscal 2025?
Relay Therapeutics reported net income of -$276.5M for fiscal 2025.
What was Relay Therapeutics' earnings per share (EPS) in fiscal 2025?
Relay Therapeutics' diluted EPS was -$1.61 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Relay Therapeutics generate in fiscal 2025?
Relay Therapeutics generated -$235.9M of free cash flow in fiscal 2025.
What was Relay Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Relay Therapeutics reported revenue of $350,000.
How many shares of Relay Therapeutics are outstanding?
Relay Therapeutics reported a weighted average of 202.8 million basic shares outstanding in 2026 Q2.
What is Relay Therapeutics' market cap?
Based on its latest closing price, Relay Therapeutics (RLAY) has a market capitalization of about $3.52B.
When does Relay Therapeutics' fiscal year end?
Relay Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Relay Therapeutics headquartered?
Relay Therapeutics lists its business address in Cambridge, Massachusetts in its SEC filings.
Relay Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →